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NicheThe bone marrow niche is recognized as a central player in maintaining and regulating the behavior of hematopoi-
etic stem and progenitor cells. Speciﬁc gain-of and loss-of function experiments perturbing a range of osteolineage
cells or their secreted proteins had been shown to affect stem cellmaintenance (Calvi et al, 2003 [1]; Stier et al., 2005
[2]; Zhang et al., 2003 [3]; Nilsson et al., 2005 [4]; Greenbaum et al., 2013 [5]) and engraftment (Adam et al., 2006,
2009 [6,7]).We used speciﬁc in vivo cell deletion approaches to dissect the niche cell-parenchymal cell dependency
in a complex bonemarrowmicroenvironment. Endogenous deletion of osteocalcin-expressing (Ocn+) cells led to a
loss of T immune cells (Yu et al., 2015 [8]. Ocn+ cells express the Notch ligand DLL4 to communicate with T-
competent progenitors, and thereby ensuring T precursor production and expression of chemotactic molecules on
their cell surface for subsequent thymic seeding. In contrast, depletion of osterix-expressing (Osx+)
osteoprogenitors led to reduced B immune cells. These distinct hematopoietic phenotypes suggest speciﬁc pairing
of mesenchymal niche cells and parenchymal hematopoietic cells in the bone marrow to create unique functional
units to support hematopoiesis. Here, we present the global gene expression proﬁles of these osteolineage subtypes
utilizing a tripleﬂuorescent transgenicmousemodel (OsxCre+;Rosa-mCh+;Ocn:Topaz+) that labels Osx+ cells red,
Ocn+ cells green, and Osx+Ocn+ cells yellow. This system allows isolation of distinct osteolineage subsets within
the same animal byﬂowcytometry. Array data that have been described in our study [8] are also publically available
from NCBI Gene Expression Omnibus (GEO) with the accession number GSE66042. Differences in gene expression
may correlate with functional difference in supporting hematopoiesis.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).SpeciﬁcationsOrganism/cell
line/tissueMus musculusSex Females
Sequencer or
array typeAffymetrix Mouse Genome 430A 2.0 ArrayData format Raw data normalized
Experimental
factorsTranscriptome comparison of Osx+ and Ocn+ osteolineage
cells.Experimental
featuresIn the OsxCre+;Rosa-mCh+;Ocn:Topaz+ mouse model, Osx+
cells were labeled red, Ocn+ cells were green, and Osx+Ocn+
cells were yellow within the same animal. This system allows
isolation of osteolineage subsets within the same animal by
ﬂow cytometry and subject to microarray comparison of
global gene expression. Mice were 8–12 weeks old. Three
replicates were used for each experimental condition.Consent Allowed to reuse citing original author.
Sample source
locationNA. This is an open access article under1. Direct link to deposited data
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE66042.2. Experimental design, materials and methods
2.1. Mouse models
Eight to twelve-week-old mice were used for all the experiments
unless otherwise speciﬁed. Mice carrying a fusion of Cre recombinase
with amodiﬁed estrogen receptor (ERt) under the control of themurine
Osterix promoter (Osx-CreERt2 [9]), hereafter called OsxCre, were
crossed with mice bearing a Rosa26-loxP-stop-loxP-mcherry (Rosa-
mCh) transgene (OsxCre;Rosa-mCh). Administration of the estrogen
analog, 4-hydroxy-tamoxifen (4-OHT) to OsxCre+;Rosa-mCh+mice re-
sulted in selective Cre activation in Osx-expressing cells followed bythe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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ﬂuorophore. The red ﬂuorescent protein marks cells expressing Osx at
the time of 4-OHT injection and their progeny. Thesemicewere crossed
with mice expressing the green ﬂuorescent protein, Topaz, driven by
the osteocalcin promoter (Ocn:Topaz). In this triple transgenic model
(OsxCre+;Rosa-mCh+;Ocn:Topaz+), the osteocalcin-expressing cells
are green, the osterix expressing cells (and their descendants) are red
and cells expressing both produce yellow. All animal usage and proce-
dures performed were approved by the Institutional Animal Care and
Use Committee of Massachusetts General Hospital.
2.2. Flow cytometry
For each mouse, tibiae, femurs, iliac crests, spines, ulnae, radii, and
humeri were collected for bone marrow cells. Muscles and soft tissue
were thoroughly removed from the bones that were ﬂushed to remove
the bone marrow content. Bone fragments were cut into small frag-
ments and transferred into a pre-warmed collagenase solution
(Stemcell Technologies), for 1 h at 37° with vigorous shaking. The solu-
tion was then ﬁltered through a 40 μm ﬁlter and the ﬂow-through was
pelleted and further processed for FACS sorting or RNA extraction.
2.3. RNA isolation
Cells were sorted in 750 μl of TRIzol® (Invitrogen) and RNA was ex-
tracted according to the instructions of the manufacturer.
2.4. Microarrays
Osx+, ++ and Ocn+ cells were sorted at 6 days post tamoxifen in-
jection from 4 to 6 weeks adults by using the FACSAria. RNA was ex-
tracted using the TRIzol® (Invitrogen) according to the manufacturer's
instructions. Samples were further processed by the NuGen Ovation
V2 laboratory Process in themicroarray core facility of Dana-Farber Can-
cer Institute. Brieﬂy, ﬁrst stand cDNA was prepared from total RNA
using a DNA/RNA chimeric primer and a reverse transcriptase. The
resulting double stranded cDNA with a unique heteroduplex at the 5'
end of the antisense strand was ampliﬁed using SPIATM ampliﬁcation,
a repeated process of SPIATMDNA/RNA primer hybridization, DNA rep-
lication, strand displacement and RNA cleavage which resulted in a
rapid accumulation of cDNAwith sequence complementary to the orig-
inal RNA. The SPIATM ampliﬁed cDNAwas puriﬁed using the Zymo Re-
search DNA Clean & ConcentratorTM system. The puriﬁed cDNA was
fragmented through a chemical and enzymatic process and labeled via
enzymatic attachment of a biotin-labeled nucleotide to the 3′-hydroxyl
end of the fragmented cDNA. The biotinylated cDNAwas added to a hy-
bridization solution containing several biotinylated control oligonucleo-
tides (for quality control), and hybridized to theMouse430Amicroarray
chip overnight at 45 °C. The chips were then transferred to a ﬂuidics in-
strument that performswashes to remove cDNA that has not hybridized
to its complementary oligonucleotide probe. The bound cDNAwas then
ﬂuorescently labeled using phycoerythrin-conjugated streptavidin
(SAPE); additional ﬂuors were then added using biotinylated anti-
streptavidin antibody and additional SAPE. Each cDNAbound at its com-
plementary oligonucleotide was excited using a confocal laser scanner,
and the positions and intensities of the ﬂuorescent emissions were cap-
tured. These measures provide the basis of subsequent biostatistical
analysis. Standard QA/QC analyses involved chip analysis with the
assayQualityMetrics BioConductor package and found no signiﬁcant
quality issues with any of the chips, as determined by (among othermethods) visual inspection, intensity distributions or RNA degradation
plots.
2.5. Quality assessment
Standard QA/QC analyses involved chip analysis with the
assayQualityMetrics BioConductor package and found no signiﬁcant
quality issues with any of the chips, as determined by (among other
methods) visual inspection, intensity distributions or RNA degradation
plots. The data was background corrected and normalized with RMA
(Robust Multichip Average) using the “affy” BioConductor package.
Values in the data matrix represent log2 normalized intensity values.
3. Differential expression quantiﬁcation and classiﬁcation
Supervised learning or class prediction methods were used for mo-
lecular classiﬁcation and pattern recognition. This analysis involves
selecting the features (genes) most correlated with a phenotypic dis-
tinction of interest. These features or “marker genes” are biologically in-
teresting in themselves but they can also be used as the input of a
classiﬁcation algorithm that uses existing “labeled” samples to build a
model to predict the labels for future samples. Genes correlated with a
binary class distinction, for example a morphological or clinical pheno-
type, is directly identiﬁed and selected by using a “distance”metric, for
example t-test statistic = (mA−mB) ÷ (s2A + s2B) [m and s are the
means and std. dev. per class] or Signal to noise ratio = (mA−mB) /
(sA + sB) [m and s are the means and std. dev. per class].
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